Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Solid Tumors
67%
Advanced Solid Tumors
65%
Targeted Therapy
50%
Tumor
44%
HER2-mutant
43%
Gene Electrotransfer
42%
Copenhagen
42%
Genomic Profiling
41%
Pemigatinib
40%
Neratinib
40%
Tumor Tissue
35%
Actionable Targets
33%
HER2 mutation
33%
First-in-human
32%
Genetic Profile
32%
Basket Trial
32%
Personalized Oncology
32%
Antiangiogenic
30%
Antitumor Activity
28%
Cancer Types
28%
RNA Sequencing (RNA-seq)
26%
Fibroblast Growth Factor Receptor 1 (FGFR1)
26%
Phase I Study
26%
Immune Checkpoint Inhibitors
23%
Human Epidermal Growth Factor Receptor 2 (HER2)
23%
Treatment Options
21%
Tumor Biopsy
21%
Molecular Targets
21%
Clinical Actionability
21%
Previously Treated
20%
Phase 1 Trial
20%
Pathogenic Germline Variants
20%
Fibroblast Activation Protein
20%
Clinical Outcomes
20%
Disseminated Melanoma
20%
Plasmid
20%
Gene Therapy
20%
Metastatic Breast Cancer
20%
Checkpoint Inhibition
20%
Actionable Alterations
20%
Objective Response Rate
20%
Targeted Treatment
20%
Whole Exome Sequencing
19%
Plasmid DNA (pDNA)
18%
Patients with Advanced Cancer
17%
Atezolizumab
16%
Peripheral Blood
16%
Progression-free Survival
16%
Adverse Events
16%
Objective Response
16%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Neoplasm
54%
Adverse Event
36%
Neratinib
30%
Pemigatinib
30%
Immunotherapy
27%
Atezolizumab
27%
Pharmacodynamics
24%
Carcinogenesis
21%
Pharmacokinetics
20%
Metastatic Breast Cancer
20%
Antiangiogenic
20%
Peptide
20%
Breast Cancer
20%
Antitumor Activity
19%
Biological Marker
17%
Malignant Neoplasm
15%
Clinical Trial
14%
Fibroblast Growth Factor Receptor
14%
Diseases
13%
Cytokine Release Syndrome
13%
Fulvestrant
13%
Trastuzumab
13%
Phosphotransferase
12%
Bile Duct Carcinoma
12%
Anticarcinogen
11%
Integrin
11%
Plasmid DNA
11%
Chemotherapy Regimens
11%
Circulating Tumor DNA
10%
Fibroblast Growth Factor Receptor 1
10%
Trastuzumab Deruxtecan
10%
Interleukin 1 Receptor Accessory Protein
10%
Melanoma
10%
Human Study
10%
Biliary Tract Cancer
10%
Protein Antibody
10%
Erythropoietin
10%
Central Nervous System Tumor
10%
Luciferase
10%
CAR T-Cell Therapy
10%
Gamma Urogastrone
10%
Epidermal Growth Factor Receptor 2
10%
Phase I Trials
10%
Mercaptopurine
10%
Castration Resistant Prostate Cancer
10%
Elimination
9%
Monotherapy
9%
Progression Free Survival
9%
Maximum Tolerated Dose
7%
Medicine and Dentistry
Solid Malignant Neoplasm
69%
Genetics
62%
Neoplasm
38%
Targeted Therapy
34%
Diseases
23%
T Cell
22%
Neratinib
20%
Pemigatinib
20%
Fibroblast Growth Factor Receptor
20%
Clinical Trial
20%
Malignant Neoplasm
18%
Tumor
18%
Fibroblast Growth Factor Receptor 1
18%
Progression Free Survival
17%
Biopsy Technique
17%
Oncology
16%
Immunotherapy
15%
Carcinogenesis
15%
Tumor Biopsy
14%
Phosphotransferase
14%
Clinical Oncology
13%
Immune Checkpoint Inhibitor
13%
Cytokine Release Syndrome
13%
Molecular Profiling
13%
Fibroblast Growth Factor Receptor 3
12%
Glioblastoma
12%
Biological Marker
11%
Breast Cancer
11%
Cancer
10%
Personalized Medicine
10%
Cell-Free DNA
10%
Cervical Cancer
10%
Cancer Therapy
10%
Metastatic Breast Cancer
10%
Experimental Oncology
10%
Phase I Trials
10%
Oncologist
10%
Tumor Infiltrating Lymphocyte
10%
Patient Selection
10%
Homologous Recombination
10%
Central Nervous System Tumor
10%
CAR T-cell therapy
10%
Histology
10%
Interleukin 1 Receptor Accessory Protein
10%
Gamma Urogastrone
10%
Epidermal Growth Factor Receptor 2
10%
Circulating Tumor DNA
10%
Anticarcinogen
10%
Fibroblast
10%
Protein Antibody
10%
